---
title: "Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/285204108.md"
description: "Compass Therapeutics, Inc. reported its 1Q 2026 results, showing a revenue of $18.76M and a net loss of $18.32M, reflecting a year-over-year increase in losses. The company achieved a clinical milestone with its lead candidate, Tovecimig, in a biliary tract cancer study and received FDA Orphan Drug Designation. The financial position remains strong, with cash expected to support operations until 2028, despite a 41% rise in G&A expenses. The company is advancing multiple antibody programs and preparing for regulatory engagement."
datetime: "2026-05-05T12:11:01.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/285204108.md)
  - [en](https://longbridge.com/en/news/285204108.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/285204108.md)
---

# Compass Therapeutics, Inc. 1Q 2026: Revenue ($18.76M), EPS ($0.1) — 10-Q Summary

Compass Therapeutics, Inc. reported first-quarter 2026 results showing a larger comprehensive loss and net loss versus the prior-year quarter as the clinical-stage biopharma advances multiple antibody programs and prepares regulatory engagement for its lead candidate.

**Financial Highlights**

Metric

Current quarter

Prior year quarter

YoY change

Revenue¹

($18.76M)

($16.65M)

(12.6%)

Net income²

($18.32M)

($16.63M)

(10.1%)

Diluted EPS³

($0.1)

($0.12)

16.7%

_¹ Reported as “Comprehensive loss”. ² Reported as “Net loss”. ³ Reported as “loss per share - basic and diluted”._

**Business Highlights**

-   Clinical milestone: Tovecimig met the primary objective in a Phase 2/3 second-line biliary tract cancer study with an objective response rate of 17.1% versus 5.3% for control and showed a significant progression-free survival benefit.
-   Regulatory progress: Tovecimig received FDA Orphan Drug Designation for biliary tract cancer; the company is planning an FDA meeting ahead of a planned BLA submission.
-   Pipeline: Four clinical-stage antibody programs are active — tovecimig, CTX-471, CTX-8371 and CTX-10726 — with ongoing clinical activities.
-   Financial position: Cash and marketable securities are expected to support operations into 2028, enabling continued trials and program development.
-   Cost trends: R&D spending remained broadly stable quarter-over-quarter while G&A rose 41%, driven largely by higher stock-based compensation to support growth.

Original SEC Filing: Compass Therapeutics, Inc. \[ CMPX \] - 10-Q - May. 05, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [CMPX.US](https://longbridge.com/en/quote/CMPX.US.md)

## Related News & Research

- [Capstone Companies, Inc. announces Execution of Binding Letter of Intent with eBliss Global, Inc. | CAPC Stock News](https://longbridge.com/en/news/286782166.md)
- [Crescita Therapeutics Inc. Obtains Final Order Approving Plan of Arrangement | CRRTF Stock News](https://longbridge.com/en/news/287120809.md)
- [Kivo Launches Headless GxPTM to Power Compliant Agentic AI in Drug Development](https://longbridge.com/en/news/287071239.md)
- [Avalo Therapeutics, Inc. 1Q 2026: Revenue ($19.7M), Net income ($19.63M), EPS ($0.98) — 10-Q Summary](https://longbridge.com/en/news/286249429.md)
- [00:45 ETAraceli Biosciences Launches Endeavor® Live Cell for Ultra-High-Throughput Kinetic Imaging in AI-Driven Drug Discovery](https://longbridge.com/en/news/287006505.md)